Company Overview and News

10
Graphite Miners News For The Month Of May 2018

2018-05-30 seekingalpha
Graphite company news - Battery Minerals raises A$20m for Montepuez. Triton Minerals signs second graphite offtake deal for Ancuabe.
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE ZEYYF GPHEF IAG RNU GPHOF BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR GLKIF LMR NGPHF TLG LEMIF GLK WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

0
Talga Resources test work shows superiority of its battery graphite anode material

2018-05-15 proactiveinvestors.com.au
Talga Resources Ltd (ASX:TLG) has received performance test work results for its graphite anode material in commercial-size cells for lithium-ion batteries.
TLG

20
Graphite Miners News For The Month Of April 2018

2018-04-29 seekingalpha
Graphite company news - Syrah Resources officially opens their Balama Graphite operation in Mozambique. Triton Minerals signs first binding offtake deal with China’s Qingdao Tianshengda Graphite.
GRXXF URA SRHYY CNA IMYSY FMS MALRY TON LMRMF MIN URLNF ZENYF URRE DNI MUS IMYSF DMNKF SYR ZEYYF GLKIF IAG LMR RNU ABGPF NGPHF TLG LLG ALP LEMIF NSRC GLK KBBRF WWR ZEN CYLYF AMVMF SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF MALRF

9
Graphite Miners News For The Month Of March 2018

2018-03-31 seekingalpha
Graphite spot and contract price news - graphite prices have begun to move up boosted by an improving steel industry, a China environmental crackdown, and a strong Li-ion battery demand.
SRHYY IMYSY FMS TON ZENYF IMYSF SYR ZEYYF GLKIF IAG TORVF ABGPF NGPHF TLG LLG ALP NSRC GLK KBBRF WWR ZEN CYLYF AMVMF SYAAF KNL NSRCF MGPHF FCSMF SJL

3
Talga Resources Ltd.: Low Cost Commercial Graphene Production With Cobalt Upside

2018-03-28 seekingalpha
Partnerships with companies such as Bosch, BASF, Heidelberg Cement and Tata motors to commercialise graphene enhanced products.
TLG JMPLY JMPLF 500570 TATAMOTORS TTM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:TLG / TALGA RESOURCES LTD on message board site Silicon Investor.

Tollgrade Communications.....Nasdaq- TLGD CTLG as a Backdoor Internet play!
Check out Specialty Catalog Corp (CTLG)